Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...
“Patients with pulmonary edema generally describe breathlessness. Sometimes they feel like they are suffocating or breathing ...
Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita ...
Structural and functional pulmonary MRI measurements may predict future pulmonary exacerbations among individuals with cystic fibrosis.
“The FDA’s Breakthrough Therapy Designation for pemvidutide in MASH reinforces the promise of its clinical profile and potential to address significant unmet needs in this serious, progressive liver ...
Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...
New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary ...
Animate Biosciences Inc. has released promising preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeutic peptides significantly reduced lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback